These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35363556)

  • 1. Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle.
    Yang K; Wang C; White KI; Pfuetzner RA; Esquivies L; Brunger AT
    Proc Natl Acad Sci U S A; 2022 Apr; 119(16):e2119467119. PubMed ID: 35363556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor.
    Yang K; Wang C; Kreutzberger AJB; White KI; Pfuetzner RA; Esquivies L; Kirchhausen T; Brunger AT
    Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2300360120. PubMed ID: 36940324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein.
    Yang K; Wang C; Kreutzberger AJB; Ojha R; Kuivanen S; Couoh-Cardel S; Muratcioglu S; Eisen TJ; White KI; Held RG; Subramanian S; Marcus K; Pfuetzner RA; Esquivies L; Doyle CA; Kuriyan J; Vapalahti O; Balistreri G; Kirchhausen T; Brunger AT
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2210990119. PubMed ID: 36122200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein.
    Yang K; Wang C; Kreutzberger AJB; Ojha R; Kuivanen S; Couoh-Cardel S; Muratcioglu S; Eisen TJ; White KI; Held RG; Subramanian S; Marcus K; Pfuetzner RA; Esquivies L; Doyle CA; Kuriyan J; Vapalahti O; Balistreri G; Kirchhausen T; Brunger AT
    bioRxiv; 2022 Aug; ():. PubMed ID: 35982670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.
    Xing L; Xu X; Xu W; Liu Z; Shen X; Zhou J; Xu L; Pu J; Yang C; Huang Y; Lu L; Jiang S; Liu S
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein.
    Fan X; Cao D; Kong L; Zhang X
    Nat Commun; 2020 Jul; 11(1):3618. PubMed ID: 32681106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.
    Bosch BJ; Martina BE; Van Der Zee R; Lepault J; Haijema BJ; Versluis C; Heck AJ; De Groot R; Osterhaus AD; Rottier PJ
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8455-60. PubMed ID: 15150417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry.
    Lin X; Guo L; Lin S; Chen Z; Yang F; Yang J; Wang L; Wen A; Duan Y; Zhang X; Dai Y; Yin K; Yuan X; Yu C; He B; Cao Y; Dong H; Li J; Zhao Q; Lu G
    Emerg Microbes Infect; 2022 Dec; 11(1):1920-1935. PubMed ID: 35757908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect.
    Oliva R; Shaikh AR; Petta A; Vangone A; Cavallo L
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33946306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus.
    Xu Y; Zhu J; Liu Y; Lou Z; Yuan F; Liu Y; Cole DK; Ni L; Su N; Qin L; Li X; Bai Z; Bell JI; Pang H; Tien P; Gao GF; Rao Z
    Biochemistry; 2004 Nov; 43(44):14064-71. PubMed ID: 15518555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
    Liu S; Xiao G; Chen Y; He Y; Niu J; Escalante CR; Xiong H; Farmar J; Debnath AK; Tien P; Jiang S
    Lancet; 2004 Mar; 363(9413):938-47. PubMed ID: 15043961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
    Bi W; Chen G; Dang B
    J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2.
    Ling R; Dai Y; Huang B; Huang W; Yu J; Lu X; Jiang Y
    Peptides; 2020 Aug; 130():170328. PubMed ID: 32380200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Coronavirus Entry
    Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
    mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion.
    Gao J; Cao C; Shi M; Hong S; Guo S; Li J; Liang T; Song P; Xu R; Li N
    Phytomedicine; 2023 Sep; 118():154942. PubMed ID: 37421767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2.
    Benton DJ; Wrobel AG; Roustan C; Borg A; Xu P; Martin SR; Rosenthal PB; Skehel JJ; Gamblin SJ
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33579792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins.
    Polo-Megías D; Cano-Muñoz M; Berruezo AG; Laumond G; Moog C; Conejero-Lara F
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.